Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD7 expression in acute myeloid leukemia

G Del Poeta1, R Stasi, A Venditti

  • 1Department of Hematology, University Tor Vergata, Ospedale S. Eugenio, Rome, Italy.

Leukemia & Lymphoma
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Leukemia·2026
Same author

Lipegfilgrastim for primary prophylaxis of febrile neutropenia in patients treated for advanced-stage classical hodgkin lymphoma: successful outcomes from a multicenter cohort study.

Annals of hematology·2026
Same author

The High-Energy Ion Telescope (HIT) for the Interstellar Mapping And Acceleration Probe (IMAP) Mission.

Space science reviews·2026
Same author

The complexity of finding fit-for-purpose real-world data for oncology patients with rare <i>NTRK</i> gene fusions and a novel solution.

ESMO real world data and digital oncology·2026
Same author

IMAP's Role in Understanding Particle Injection and Energization Throughout the Heliosphere.

Space science reviews·2026
Same author

Precision Spectral Measurements of Chromium and Titanium from 10 to 250  GeV/n and Sub-Iron to Iron Ratio with the Calorimetric Electron Telescope on the International Space Station.

Physical review letters·2025
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

CD7 antigen expression in acute myeloid leukemia (AML) indicates poorer treatment outcomes. CD7-positive AML patients showed lower complete remission rates and reduced survival, especially when co-expressing CD14.

Area of Science:

  • Hematology
  • Oncology
  • Immunophenotyping

Background:

  • CD7 antigen expression is observed in various hematologic malignancies.
  • Its role in acute myeloid leukemia (AML) prognosis requires further elucidation.

Purpose of the Study:

  • To evaluate the clinical significance of CD7 antigen expression on leukemic blasts in de novo acute myeloid leukemia (AML).

Main Methods:

  • Analyzed 207 de novo AML patients, focusing on 53 CD7-positive cases.
  • Utilized flow cytometry for immunophenotypic analysis, including CD34 and P-glycoprotein (P-170) expression.
  • Correlated CD7 expression with French-American-British (FAB) subtypes, clinical parameters, and treatment outcomes.

Main Results:

Related Experiment Videos

  • CD7 positivity was associated with higher white blood cell counts and increased CD34 expression, suggesting immature leukemic cells.
  • A significant correlation was found between CD7 and P-170 positivity.
  • CD7-positive AML patients exhibited significantly lower complete remission rates (32% vs. 74%) and poorer overall and disease-free survival compared to CD7-negative patients.
  • Coexpression of CD14 in CD7-positive AML was linked to a particularly unfavorable prognosis.

    • Conclusions:

    • CD7 antigen expression on leukemic blasts is a significant adverse prognostic factor in de novo AML.
    • CD7 positivity is associated with unfavorable clinical and biological features and reduced treatment efficacy.
    • CD7 and CD14 coexpression identifies a high-risk AML subgroup requiring intensified therapeutic strategies.